Economics

This channel highlights factors that impact hospital and healthcare economics and revenue. This includes news on healthcare policies, reimbursement, marketing, business plans, mergers and acquisitions, supply chain, salaries, staffing, and the implementation of a cost-effective environment for patients and providers.

RSS icon
Qure.ai CEO and Co-founder Prashant Warier

Radiology vendor Qure.ai completes $65M Series D funding round

Founded in 2016, the vendor offers the "world’s most deployed healthcare AI," with its solutions in use across 3,000 care sites in 90 countries. 

wisconsin baldwin rural healthcare

HHS awards $75M for addiction and maternal health services in rural areas

The funds will be used to expand services and improve the financial stability of existing healthcare organizations located in underserved regions of the South. 

Lumus Imaging

Private equity firm acquiring diagnostic imaging provider for $658M

Affinity Equity Partners is buying 30-year-old Lumus Imaging, which employs over 2,000 imaging experts and support staff across 150 care sites. 

The FreeClimb 70 reperfusion system with Tenzing 7 delivery catheter. Image courtesy of Route 92 Medical.

Stroke specialists raise another $50M thanks to late investment from Novo Holdings

California-based Route 92 Medical previously announced a funding round worth more than $31 million in November. Now, however, a massive addition from Novo Holdings makes the round worth closer to $82 million. 

Erin R. Stevens, CNMT, NCT, director of nuclear medicine at Oregon Heart Center, said training physicians for what is needed in cardiac PET documentation is key for preventing issues with prior authorizations. ASNC photo

Good documentation is the key to cardiac PET prior authorizations

Knowing what, exactly, is needed in cardiac PET documentation is one of the best ways to limit prior authorization issues.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Most recalled cardiovascular devices gained FDA approval with little to no clinical evidence

Why are so many cardiovascular devices involved in Class I recalls? One possible reason could be the large number of devices hitting the market without undergoing much premarket clinical testing. 

Telix Pharmaceuticals

Imaging agent developer Telix to buy RLS radiopharmaceutical network for up to $250M

RLS operates America’s only Joint Commission-accredited radiopharmacy network, with 31 locations covering over 85% of the U.S. population. 

healthcare surprise billing statement payment

60% of radiologists and other docs surveyed say staff is devoting more time to billing compliance

Meanwhile, about two-thirds of physicians said staff hours devoted to processing prior authorizations had also risen in the past five years. 

Displaying 121 - 128 of 3758
Design by Adaptive Theme